实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2015年
2期
205-207
,共3页
非小细胞肺癌%培美曲塞%顺铂%吉西他滨
非小細胞肺癌%培美麯塞%順鉑%吉西他濱
비소세포폐암%배미곡새%순박%길서타빈
Non-small cell lung cancer%Pemetrexed%Cisplatin%Gemcitabine
目的：探讨培美曲塞联合顺铂治疗晚期非小细胞肺癌的疗效和安全性。方法将92例晚期非小细胞肺癌患者随机分入培美曲塞组及吉西他滨组，2组患者分别接受培美曲塞或吉西他滨联合顺铂治疗。比较2组患者1年及2年生存率、近期疗效、中位生存时间及不良反应发生率。结果培美曲塞组1年及2年生存率分别为64．2％和35．7％，吉西他滨组分别为61．9％和31．0％，差异无统计学意义（P＞0．05）；2组中位生存时间分别为16．8个月和17．1个月（P＞0．05）。吉西他滨组与培美曲塞组治疗有效率分别为80．9％和83．3％，总缓解率分别为45．2％和42．9％（P＞0．05）；培美曲塞组患者Ⅲ～Ⅳ级骨髓抑制发生率显著低于吉西他滨组（11．9％vs 45．2％，P＜0．05）；治疗后培美曲塞组患者KPS评分显著优于吉西他滨组（P＜0．05）。结论培美曲塞与吉西他滨分别联合顺铂治疗晚期非小细胞肺癌的临床疗效相当，但前者不良反应小，患者生活质量优于后者。
目的：探討培美麯塞聯閤順鉑治療晚期非小細胞肺癌的療效和安全性。方法將92例晚期非小細胞肺癌患者隨機分入培美麯塞組及吉西他濱組，2組患者分彆接受培美麯塞或吉西他濱聯閤順鉑治療。比較2組患者1年及2年生存率、近期療效、中位生存時間及不良反應髮生率。結果培美麯塞組1年及2年生存率分彆為64．2％和35．7％，吉西他濱組分彆為61．9％和31．0％，差異無統計學意義（P＞0．05）；2組中位生存時間分彆為16．8箇月和17．1箇月（P＞0．05）。吉西他濱組與培美麯塞組治療有效率分彆為80．9％和83．3％，總緩解率分彆為45．2％和42．9％（P＞0．05）；培美麯塞組患者Ⅲ～Ⅳ級骨髓抑製髮生率顯著低于吉西他濱組（11．9％vs 45．2％，P＜0．05）；治療後培美麯塞組患者KPS評分顯著優于吉西他濱組（P＜0．05）。結論培美麯塞與吉西他濱分彆聯閤順鉑治療晚期非小細胞肺癌的臨床療效相噹，但前者不良反應小，患者生活質量優于後者。
목적：탐토배미곡새연합순박치료만기비소세포폐암적료효화안전성。방법장92례만기비소세포폐암환자수궤분입배미곡새조급길서타빈조，2조환자분별접수배미곡새혹길서타빈연합순박치료。비교2조환자1년급2년생존솔、근기료효、중위생존시간급불량반응발생솔。결과배미곡새조1년급2년생존솔분별위64．2％화35．7％，길서타빈조분별위61．9％화31．0％，차이무통계학의의（P＞0．05）；2조중위생존시간분별위16．8개월화17．1개월（P＞0．05）。길서타빈조여배미곡새조치료유효솔분별위80．9％화83．3％，총완해솔분별위45．2％화42．9％（P＞0．05）；배미곡새조환자Ⅲ～Ⅳ급골수억제발생솔현저저우길서타빈조（11．9％vs 45．2％，P＜0．05）；치료후배미곡새조환자KPS평분현저우우길서타빈조（P＜0．05）。결론배미곡새여길서타빈분별연합순박치료만기비소세포폐암적림상료효상당，단전자불량반응소，환자생활질량우우후자。
Objective To explore the efficacy and safety of pemetrexed and cisplatin in the treatment of advanced non-small cell lung cancer.Methods 92 cases of advanced non-small cell lung cancer were divided into pemetrexed group and gem-citabine group.The 2 groups respectively received pemetrexed or gemcitabine combined with cisplatin.1-,2-year survival rates, short term effect,median survival time and side effects were compared between the 2 groups.Results 1-,2-year survival rates were 64.2%and 35.7%in pemetrexed group,and those of gemcitabine group were 61.9%and 31.0%,there had no significant difference(P>0.05);Median survival time were 16.8 and 17.1 months in the 2 groups (P>0.05);Effective rates of gemcit-abine group and pemetrexed group were 80.9%and 83.3%,and overall response rates were 45.2% and 42.9% (P>0.05);Ⅲ~Ⅳgrade of myelosuppression in pemetrexed group was much lower than that of gemcitabine group (11.9%vs 45.2%,P<0.05);KPS scores after treatment in pemetrexed group was superior to gemcitabine group (P<0.05).Conclusion Pemetrexed or gemcitabine combined with cisplatin have similar effect for advanced non-small cell lung cancer.Pemetrexed has less adverse reaction and better life quality.
